Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ... The patient died after experiencing acute liver ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...

Patient was a 16-year-old teen, who underwent treatment in Dec First death reported ... acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys ... crossed over to receive Elevidys after initially ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy ... noted that over 800 patients have now been treated with the therapy.

The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy community. The patient died from acute liver failure months after starting ...

The patient, a young man, suffered acute liver failure after receiving the therapy ... death. Fatalities have also been reported following the launch of Novartis’s Zolgensma, an AAV-delivered ...

Yet on Tuesday, Sarepta shares sank as much as 25% after the company reported the death of a young man from acute liver failure following treatment with its gene therapy. The news was ...

(Reuters) - Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.